Medicare Begins to Rein In Drug Costs for Older Americansnews2023-01-14T16:52:43+00:00January 14th, 2023|The New York Times|
Diabetes Management Tech for Type II patients: Interview with Jeffrey Brewer, CEO of Bigfoot Biomedicalnews2022-12-02T02:11:03+00:00December 2nd, 2022|Medgadget|
¿Qué es Ozempic y por qué genera tantos comentarios en internet?news2022-11-23T13:52:31+00:00November 23rd, 2022|The New York Times|
What Is Ozempic and Why Is It Getting So Much Attention?news2022-11-22T16:48:50+00:00November 22nd, 2022|The New York Times|
FDA Approves a Drug That Can Delay Type 1 Diabetesnews2022-11-18T21:52:11+00:00November 18th, 2022|The New York Times|
La larga espera por la cura de la diabetesnews2022-08-17T07:00:08+00:00August 17th, 2022|The New York Times|
Samples of Popular Diabetes Drug Contain Potential Carcinogen, F.D.A. Saysnews2022-08-11T19:37:20+00:00August 11th, 2022|The New York Times|
Medicare Recipients Could Find Drug Cost Relief in Health Billnews2022-08-10T07:00:11+00:00August 10th, 2022|The New York Times|
The Long, Long Wait for a Diabetes Curenews2022-08-09T07:00:10+00:00August 9th, 2022|The New York Times|
The Doctor Prescribed an Obesity Drug. Her Insurer Called It ‘Vanity.’news2022-05-31T22:23:09+00:00May 31st, 2022|The New York Times|
